ADC Therapeutics SA (ADCT) Misses Q3 EPS by 1c; Reports $530.2M of Cash and Cash Equivalents
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts ADCT Hot Sheet
Join SI Premium – FREE
ADC Therapeutics SA (NYSE: ADCT) reported Q3 EPS of ($0.93), $0.01 worse than the analyst estimate of ($0.92). Revenue for the quarter came in at $13.1 million versus the consensus estimate of $7.39 million.
For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- North American Construction (NOA) Misses Q3 EPS by 27c; Offers Guidance
- Innoviva (INVA) Misses Q3 EPS by 156c
Create E-mail Alert Related Categories
Corporate News, EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
